| human | Q5 |
| P6178 | Dimensions author ID | 014627217634.42 |
| P10861 | Springer Nature person ID | 014627217634.42 |
| P735 | given name | Caroline | Q16275172 |
| Caroline | Q16275172 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q33241773 | 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q33354606 | A family history of breast cancer will not predict female early onset breast cancer in a population-based setting |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q33202841 | A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone |
| Q33361124 | A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours |
| Q33377470 | A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q39347401 | A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships |
| Q35611919 | A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG |
| Q57560944 | Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 |
| Q36210166 | Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. |
| Q33496999 | Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q35705287 | Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis |
| Q33185597 | Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer |
| Q35927942 | An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients |
| Q33901361 | An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q44224358 | Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q52373876 | Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. |
| Q49223626 | Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer. |
| Q33747361 | BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q35062077 | Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group |
| Q57947357 | Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: A prospective long-term follow-up study |
| Q57947254 | Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q44602623 | Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations |
| Q34084471 | Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation |
| Q41195564 | Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q33179295 | Breast cancer screening in high-risk women. Rotterdam Committee of Medical and Genetic Counseling |
| Q34432389 | Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q37397658 | CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer |
| Q57561007 | CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial |
| Q48030851 | CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial |
| Q46799385 | Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients |
| Q36898774 | Chemotherapy in metastasized breast carcinoma |
| Q36465283 | Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases |
| Q33184753 | Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation |
| Q43207245 | Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors |
| Q73862163 | Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q57947612 | Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress |
| Q33180784 | Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer |
| Q33284409 | Controlling cancer chemotherapy-induced emesis |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
| Q33283806 | Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy |
| Q33964841 | Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment |
| Q38297766 | Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature |
| Q33303403 | Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients |
| Q37279308 | Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial |
| Q53547155 | Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q33522383 | Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy |
| Q33181647 | Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk |
| Q34278391 | Effects of CYP induction by rifampicin on tamoxifen exposure |
| Q43168160 | Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial |
| Q36565659 | Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis |
| Q27851630 | Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial |
| Q47127824 | Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q57947710 | Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer |
| Q42696965 | Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial |
| Q35125211 | External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q33247548 | Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer |
| Q61970236 | Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors? |
| Q46748275 | Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q33348120 | GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q57561023 | Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial |
| Q48743460 | Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. |
| Q48229486 | Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy |
| Q33296147 | Gynaecological sarcomas |
| Q38431354 | HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q46841926 | Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition |
| Q47213769 | High satisfaction rates in women after DIEP flap breast reconstruction |
| Q33177624 | High-dose chemotherapy in adult sarcomas: no standard yet. |
| Q51607992 | Hypersensitivity reactions to CHIP. |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q38677974 | Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q36625994 | Impact of screening for breast cancer in high-risk women on health-related quality of life |
| Q33289378 | Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment |
| Q43677630 | Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis |
| Q49063139 | Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. |
| Q43623571 | Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis |
| Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q33202360 | Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy |
| Q33182519 | Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q38114578 | Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia |
| Q48046482 | Late effects of adjuvant chemotherapy for breast cancer on fine motor function |
| Q57947297 | Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile |
| Q51016879 | Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. |
| Q33339945 | Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q37692442 | Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy |
| Q34257381 | MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk |
| Q36095933 | MUTYH gene variants and breast cancer in a Dutch case–control study |
| Q45364320 | Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study |
| Q38026242 | Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q53377954 | Micrometastases or isolated tumor cells and the outcome of breast cancer. |
| Q57560981 | Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: A Dutch TEAM trial analysis |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q48005561 | Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant |
| Q33731350 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine |
| Q36323913 | Most women recover from psychological distress after postoperative complications following implant or DIEP flap breast reconstruction: A prospective long-term follow-up study |
| Q36870806 | Multidisciplinary treatment of superior sulcus (Pancoast) tumors |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q54334315 | Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. |
| Q40050035 | Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study |
| Q44498338 | Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
| Q36859620 | Novel endocrine therapies in breast cancer |
| Q74630656 | Occult cancer in the fallopian tube in patients with a BRCA-1 germline mutation |
| Q53708801 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. |
| Q68426617 | Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin |
| Q52375755 | One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). |
| Q50862667 | Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. |
| Q37408259 | Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q50760539 | Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. |
| Q33523297 | Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q50913029 | Passive coping and psychological distress in women adhering to regular breast cancer surveillance. |
| Q33245513 | Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear |
| Q53071815 | Patients' preferences for breast reconstruction: a discrete choice experiment. |
| Q43252177 | Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial |
| Q33357640 | Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer |
| Q33181560 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients |
| Q33361664 | Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group |
| Q33182035 | Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane |
| Q33224179 | Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q47723375 | Possible consequences of applying guidelines to healthy women with a family history of breast cancer |
| Q33214894 | Practice guideline 'Diagnostic techniques for soft tissue tumours and treatment of soft tissue sarcomas (revision)' |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q73966464 | Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation |
| Q48390829 | Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy |
| Q33646928 | Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families |
| Q33229642 | Preventive surgical prcedures for inherited risk of breast cancer |
| Q33217927 | Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy |
| Q37352090 | Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor |
| Q57947628 | Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing |
| Q33181380 | Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q33286372 | Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic |
| Q42638372 | Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life |
| Q50748111 | Psychological distress and breast self-examination frequency in women at increased risk for hereditary or familial breast cancer. |
| Q57947742 | Psychological distress in women at increased risk for breast cancer: the role of risk perception |
| Q51650778 | Psychological distress in women at risk for hereditary breast cancer: the role of family communication and perceived social support. |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q36095985 | Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q58597644 | Radiation Dose-Response For Risk Of Myocardial Infarction In Breast Cancer Survivors |
| Q33325046 | Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer |
| Q59305087 | Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q51245901 | Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. |
| Q48572660 | Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. |
| Q38001912 | Relevant impact of central pathology review on nodal classification in individual breast cancer patients |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q33241693 | Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women |
| Q48904774 | Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. |
| Q33476082 | Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q35977371 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers |
| Q34361811 | Severe akathisia as a side effect of metoclopramide |
| Q39488111 | Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study |
| Q43859256 | Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis |
| Q33425460 | Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy |
| Q34663394 | Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis |
| Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
| Q33228316 | Survival and prognostic factors in BRCA1-associated breast cancer |
| Q44501566 | Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. |
| Q33179111 | Survival in hereditary breast cancer associated with germline mutations of BRCA2. |
| Q33215100 | Tailoring breast cancer therapy to genetic status |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q33204198 | Targeted therapy: ready for prime time? |
| Q33323936 | The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy |
| Q50758645 | The Distress Thermometer assessed in women at risk of developing hereditary breast cancer. |
| Q57266603 | The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians |
| Q57947566 | The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study |
| Q57947397 | The contribution of self-esteem and self-concept in psychological distress in women at risk of hereditary breast cancer |
| Q50919408 | The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. |
| Q33962070 | The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q34253646 | The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer |
| Q57947728 | The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer |
| Q51439613 | The impact of social and personal resources on psychological distress in women at risk for hereditary breast cancer. |
| Q41019747 | The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis |
| Q33308460 | The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas |
| Q35079738 | The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis |
| Q33179002 | The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q34687019 | Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q36814437 | Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer |
| Q33260860 | Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer |
| Q41671579 | Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer |
| Q35443960 | Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant |
| Q33274376 | Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases |
| Q54775737 | Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation |
| Q33228022 | Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care |
| Q35881755 | Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial |
| Q38445351 | Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries |
| Q51287680 | [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer]. |
Search more.